Renal injury caused by tenofovir disoproxil fumarate in a patient with liver cancer complicated with HBV infection：a case report and literature analysis
- VernacularTitle:肝癌合并HBV感染患者使用富马酸替诺福韦二吡呋酯致肾损伤1例并文献分析
- Author:
Lei CAO
1
,
2
;
Feng WANG
1
,
2
;
Jiyong LIU
1
,
2
;
Yingying CHANG
1
Author Information
1. Dept. of Pharmacy，Fudan University Shanghai Cancer Center，Shanghai 200032，China
2. Dept. of Clinical Oncology，Shanghai Medical College of Fudan University，Shanghai 200032，China
- Publication Type:Journal Article
- Keywords:
tenofovir disoproxil fumarate;
hepatitis B virus;
liver cancer;
renal injury;
adverse drug reaction;
literature
- From:
China Pharmacy
2024;35(7):866-871
- CountryChina
- Language:Chinese
-
Abstract:
Tenofovir disoproxil fumarate （TDF） is a first-line treatment for chronic hepatitis B. With increasing use worldwide， the adverse events of renal injury caused by this drug have also attracted industry attention. This article reports a 61- year-old patient with liver cancer complicated with hepatitis B virus （HBV） infection. The patient started using TDF in mid-March 2022 and developed kidney injury after 2 months of treatment， during which he received 2 courses of donafenib combined with sintilimab chemotherapy and irregular administration of diclofenac for pain relief. In this paper， Naranjo’s assessment scale was used to evaluate the drugs that may be associated with renal injury， including TDF and sintilimab， and the drugs that are suspected to be associated with renal injury are donafenib and diclofenac. The renal injury caused by TDF can be judged according to the changes in the patient’s condition， the incidence of drug-induced renal injury， clinical manifestations， occurrence time， occurrence mechanism， drug combination， and high-risk factors. The changes of serum creatinine in patients with liver cancer complicated with HBV infection after TDF should be dynamically monitored in the clinic， and the dose of antiviral drugs should be adjusted if necessary and other antiviral drugs with less impact on renal function can be selected， to provide individualized medication recommendations for tumor patients， reduce the incidence of TDF-related renal injury.
